SoftServe Offers Complimentary Assessment for In-Store Social Distancing Solution
28.7.2020 14:00:00 EEST | Business Wire | Press release
SoftServe, a leading digital authority and consulting company, is offering a complimentary assessment through September 30, 2020 for its In-Store Social Distancing Solution, a cloud-based computer vision and mobile app solution that offers retailers a 360-degree customer view through AI-powered advanced analytics to support value-led decision making through actionable insights. This solution enables stores to provide a secure shopping environment for customers and employees while remaining compliant with government mandated social distancing regulations, as well as track customer engagement to understand future buying dynamics and optimize store layouts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005019/en/
SoftServe's In-Store Social Distancing Solution mobile interface. (Photo: Business Wire)
Computer vision is a form of artificial intelligence (AI) that trains computers to interpret and understand digital images from cameras and videos. Computers can ‘learn’ to accurately identify and classify objects, and then react to and report on what they ‘see’. It’s a rapidly growing platform for real-time store management and enhanced operations. By 2021, 40% of retailers will implement computer vision in their customer service and support workflow, and vendors employing computer vision in retail will see a 20% lift in conversion.1
“SoftServe’s in-store social distancing solution is bridging a critical gap for retailers, ensuring a safe shopping environment through the COVID-19 pandemic while providing a valuable long-term solution for continual security, future growth, and consumer engagement,” said Valentyn Kropov, VP, client success at SoftServe. “Our solution works with your existing in-store equipment and can be ‘retrained’ around future scenarios, giving you a foundation on which to optimize store operations and customer experience for years to come.”
Ensure Customer and Employee Safety and Social Distancing Regulatory Compliance
- Mask and Temperature Detection—detect if patrons are wearing masks and scan customers’ temperatures with an infrared thermometer upon entry.
- Manage Store Capacity—count the number of patrons entering and exiting the store and provide entry permission alerts and QR code vouchers through a mobile app.
- Avoid Physical Lines—track designated distance between queued customers, provide department wait times and information through digital signage, and allow patrons to reserve spots in line.
Identify and Understand Customers’ Buying Dynamics
- Real-Time Data Processing—get actionable insights in the moment with a self-learning system that fully automates data collection.
- In-Store Customer Tracking—understand your customers’ in-store movements and product engagement better with demographics and heatmap analysis.
- Create More Immersive Shopping Experiences—learn customer interaction points and deploy AI-driven dynamic in-store advertisements. Use location analytics to optimize store layout and product positioning around customer preferences.
SoftServe’s In-Store Social Distancing Solution integrates with a store’s existing CCTV infrastructure and software platforms and can be rapidly deployed to be up and running in a couple of weeks. It’s designed to be scalable for hundreds of stores, yet is customizable around the specific business needs of each individual store.
Book your complimentary assessment and demo through the end of September today. Contact RetailDemo@softserveinc.com for a timely evaluation of your store environment to identify the most cost-efficient solution.
1 Nick Ingelbrecht, Anthony Bradley “Emerging Technologies: Top Advanced Computer Vision Use Cases for Retail”, Gartner, April 23, 2020
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005019/en/
Contact information
Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
